Esophageal cancer

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Retrieved on: 
Thursday, March 28, 2024
Other Health, Health, Science, Research, Oncology, Cancer, Incidence, Risk, Esophageal cancer, Patient, Education, Mayo Clinic, Hepatology, EAC, Exact sciences, DNA, MD, Division, HGD, FDA, Food, Medical device

“In collaborating with Exact Sciences, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC.

Key Points: 
  • “In collaborating with Exact Sciences, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC.
  • “In esophageal cancer, earlier screening and detection will provide an important advance, as we have seen in other cancers.
  • We are collaborating with Mayo Clinic to continue the development of the Oncoguard Esophagus test as a minimally invasive solution for earlier detection of EAC and its precursors.”
    The Oncoguard Esophagus test is currently under development and features of the test described above are outlining current development goals.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Retrieved on: 
Thursday, March 14, 2024
Cardiology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Civil service commission, Glucose, Survival, ALT, DSM-IV codes, Associate, Blas, Medicine, Patient, Esophageal cancer, Committee, Sodium, Alkaline phosphatase, University, Cancer, EMA, BGNE, Quality of life, Tislelizumab, Lung cancer, Section, European Medicines Agency, Lymphocyte, ITT, European Commission, Anemia, Division, ESCC, Fatigue, University of Southern California, BLA, Food, Pharmaceutical industry

TEVIMBRA will be available in the U.S. in the second half of 2024.

Key Points: 
  • TEVIMBRA will be available in the U.S. in the second half of 2024.
  • The FDA is also reviewing Biologics License Applications (BLAs) for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC and patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
  • BeiGene has launched more than 17 potentially registration-enabling trials with TEVIMBRA, of which 11 Phase 3 randomized trials and four Phase 2 trials have already had positive readouts.
  • More than 900,000 patients have been prescribed TEVIMBRA globally to date.

Spatially Health Names Leigh Ann Ruggles to Its Advisory Board to Drive Healthcare Innovation and Growth

Retrieved on: 
Tuesday, March 12, 2024
Health, GTM, GuideWell, Accountable care organization, Organization, ECAN, Advisory board, Acos, Health equity, Patient, Esophageal cancer, Acquisition, Equity, SDOH, Social determinants of health, Marketing

MIAMI, March 12, 2024 /PRNewswire-PRWeb/ -- Spatially Health, a cloud-based, health equity platform focused on identifying and addressing social determinants of health (SDOH) and health equity barriers, is excited to announce the appointment of healthcare leader Leigh Ann Ruggles as its newest Advisory Board member. Leigh Ann will play a pivotal role in shaping the company's strategic vision and decision-making.

Key Points: 
  • MIAMI, March 12, 2024 /PRNewswire-PRWeb/ -- Spatially Health , a cloud-based, health equity platform focused on identifying and addressing social determinants of health (SDOH) and health equity barriers, is excited to announce the appointment of healthcare leader Leigh Ann Ruggles as its newest Advisory Board member.
  • As a proven healthcare leader with expertise in driving business growth and market share for digital health companies, Leigh Ann is dedicated to identifying tangible solutions to tackle the increase in healthcare expenses, limited accessibility, and disparities in care.
  • "I am honored to welcome Leigh Ann Ruggles to our Advisory Board," stated Dr. Hillit Meidar-Alfi , the CEO and co-founder of Spatially Health.
  • Before Onlife Health, Leigh Ann led the Go-to-Market (GTM) organizations for both MDLIVE, a leading telehealth provider, as well as Verizon Mobile Health.

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

Retrieved on: 
Tuesday, February 20, 2024
Marie Cassidy, Prophase, Barrett's esophagus, Patent, Gastroenterology, LDT, Risk, Cancer, GI, Mayo Clinic, The Wall Street Journal, Clinical professor, Patient, Carcinogenesis, Clinical trial, Genomics, Esophageal cancer, Plague

This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.

Key Points: 
  • This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
  • If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024.
  • Recently, an additional 139 specimens were analyzed in collaboration with The Mayo Clinic, for the purposes of assessing the test's precision and reliability in identifying esophageal adenocarcinoma risk.
  • - The test has demonstrated molecular precision in excess of 99%1, which is a remarkably precise accomplishment in cancerous tissue analysis.

Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists

Retrieved on: 
Wednesday, March 6, 2024
Consensus, HGD, Dysplasia, Goldblum, LGD, Cleveland Clinic, Marie Cassidy, CDX, Doctor of Philosophy, Intraepithelial neoplasia, Brigham and Women's Hospital, Barrett's esophagus, Hospital, Diagnosis, Mayo Clinic, Health, Patient, EAC, MPH, Clinical and Translational Gastroenterology, Esophageal cancer, Neoplasm, Yale School of Medicine, Esophagus, Gastroenterology, Tufts Medical Center, Medical imaging

WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.

Key Points: 
  • WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.
  • This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett's esophagus.
  • The pathologists were then asked to evaluate digital images from 60 WATS3D cases with BE.
  • "The significant variability among pathologists assessing Barrett's esophagus poses challenges for accurate diagnosis and treatment decisions, complicating patient care."

FDA Grants Fast Track Designation to 9MW2821

Retrieved on: 
Tuesday, February 27, 2024
DCR, Carcinoma, Immunotherapy, Cervical cancer, FDA, Food, ESCC, Fast track (FDA), PD-1, Apoptosis, ADC, FTD, UC, Cell membrane, Patient, Esophageal cancer, Fine chemical

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").

Key Points: 
  • SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").
  • 9MW2821 is the world's first Nectin-4-targeting drug to disclose clinical efficacy data for the indication of EC.
  • After injection, 9MW2821 can specifically bind to Nectin-4 on the cell membrane surface, be internalized and release cytotoxic drug, and induce the apoptosis of tumor cells.
  • 9MW2821 is also the first to disclose preliminary clinical efficacy data for the indication of CC among drugs with the same target in the world.

Michael F. Price Memorial Grant from the DeGregorio Family Foundation Awarded for Esophageal Cancer Research

Retrieved on: 
Wednesday, February 21, 2024
Stomach cancer, Neoplasm, De Gregorio, Doctor of Philosophy, MD, Immunotherapy, Esophageal cancer, Grant, Cancer, Mitochondrion, Associate, Patient, Protein, Baylor College of Medicine, Research, Mouse, Baylor University, Pharmaceutical industry

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • Normally, the tumor cell 'energy center', called the mitochondria, protect the tumor cell from treatment with either chemotherapy or immunotherapy.
  • "The support of the DeGregorio Family Foundation is critical to the success of our research; we very much appreciate it," said Dr. Ripley.
  • The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised more than $8 million to fund innovative research to cure gastric and esophageal cancers.

Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts

Retrieved on: 
Tuesday, January 23, 2024
Name, Esophageal cancer, PMI, Genomics, Nebula Genomics, Therapy, Automation, Engineering, Fine chemical

Garden City, NY, Jan. 23, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today announces significant progress at Pharmaloz Manufacturing, Inc. (PMI), its wholly owned subsidiary.

Key Points: 
  • With the implementation of recent price increases across its entire product line, PMI has transitioned to significant projected 2024 profitability starting with Q1 2024.
  • In addition to the price increases, increased capacity and transition to profitability, PMI has signed deals with two top-tier lozenge brands.
  • One of these brands is also poised to leverage PMI's comprehensive blister packing capabilities, further diversifying its manufacturing portfolio.
  • This production capacity could be further increased, if demand warrants it, with additional staffing to extend the workweek.

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Retrieved on: 
Monday, December 11, 2023
MSD, Pembrolizumab, Stomach, Lenvatinib, Hepatocellular carcinoma, Research, Carboplatin, Progression-free survival, MSI-H, Disease, Merck & Co., Standard of care, Head, RCC, Cancer, Merck, Patient, OS, PFS, Eisai, Paclitaxel, Esophageal cancer, LEAP, Senior, Pharmaceutical industry

The safety profile of LENVIMA plus KEYTRUDA was consistent with that observed in previously reported studies evaluating the combination.

Key Points: 
  • The safety profile of LENVIMA plus KEYTRUDA was consistent with that observed in previously reported studies evaluating the combination.
  • We are grateful to the patients, their loved ones, and the investigators whose participation is what makes scientific advancement possible."
  • LENVIMA plus KEYTRUDA is approved in the U.S., the EU, Japan and other countries for the treatment of certain types of advanced endometrial carcinoma following prior systemic therapy in any setting and advanced renal cell carcinoma (RCC).
  • Results from the LEAP-001 trial do not affect the current approved indications for the KEYTRUDA plus LENVIMA combination or other ongoing trials from the LEAP clinical program.

A new happy place just in time for this family's Christmas.

Retrieved on: 
Thursday, December 21, 2023
Cancer, CBH, Family, Holiday, Paint, Multiple sclerosis, Esophageal cancer, My Happy Place, News, Interior design

Bethany Zimmerman, the recipient of the My Happy Place bedroom makeover, received the news that she had esophageal cancer, in a matter of weeks, she was told ‘you have stage 4 metastatic cancer’.

Key Points: 
  • Bethany Zimmerman, the recipient of the My Happy Place bedroom makeover, received the news that she had esophageal cancer, in a matter of weeks, she was told ‘you have stage 4 metastatic cancer’.
  • Said Sara Adams, President of My Happy Place Treasure Valley.
  • If you’d like to support My Happy Place and donate to Bethany’s Happy Place, go here .
  • This holiday season, they are dedicated to making a positive impact in the lives of those around them.